JN
Insider
Jason Raleigh Nunn
DirectorJason Raleigh Nunn (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Zenas BioPharma, Inc. (ZBIO). Across 1 priced purchase filing, the average 21-session return was +23.8% from execution and +35.5% from disclosure (delay-adjusted; derived). The largest single filing was $1.2M of ZBIO (63,158 sh × $19.00, as filed), executed Oct 9 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+23.8%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+35.5%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
5d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.2M
shares × price, as filed
Last traded
Oct 9 2025
Filed Oct 14 2025
Volume by month
Buys $1.2M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
ZBIORecent filings
ZBIOPURCHASE
Zenas BioPharma, Inc.
View filing →
$1.2M63,158 sh × $19.00
Exec Oct 9 2025
Filed Oct 14 2025 · 5:16 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. View filing → $15.0M
882,352 sh across 2 lots
Exec Sep 16 2024
Filed Sep 16 2024 · 5:30 PM ET